Technical Articles

Among the four FGFR family members, FGFR4 alone resides in the liver and binds the KLB co-receptor. From an industry perspective, this article dissects the FGF19 axis, its association with hepatocellular carcinoma and the design logic of selective in

The FGFR4 door opens only when both keys—FGF19 and KLB—are inserted at the same time. This article walks through the four-step assembly of the FGF19-FGFR4-KLB ternary complex and the full process of signal entry.

FGFR4 (fibroblast growth factor receptor 4) is an important member of the receptor tyrosine kinase family, and its signaling pathway plays a key role in regulating cell proliferation, differentiation and immune response. In recent years, the predictive value of FGFR4 mutation in immunotherapy of non-small cell lung cancer (NSCLC) has gradually attracted attention. Many studies have shown that FGFR4 mutation is not only significantly associated with the efficacy of immunotherapy, but also affects the treatment response by reshaping the tumor immune microenvironment, providing a new molecular target for optimizing immunotherapy strategies.